The future of the quinolones

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 1-5

  Andriole, Vincent T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 8 DIFLUOROMETHOXY 6 FLUORO 1,4 DIHYDRO 7 (3 METHYL 1 PIPERAZINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTACID AGENT; BALOFLOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; CYCLOSPORIN; ECENOFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LOMEFLOXACIN; MOXIFLOXACIN; NADIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; PAZUFLOXACIN; PD 140288; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RUFLOXACIN; SITAFLOXACIN; SPARFLOXACIN; THEOPHYLLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; LEUKOPENIA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PELVIC INFLAMMATORY DISEASE; PHOTOTOXICITY; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; THROMBOCYTOPENIA;

BACTERIA (MICROORGANISMS); PNEUMOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032726667     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00001     Document Type: Conference Paper

References (57)

1. Neu HC. The quinolones: prospects. In: Andriole VT, editor. The quinolones. London: Academic Press, 1988: 235-54
2. Andriole VT. The future of the quinolones. Drugs 1993; Suppl. 3: 1-7
3. Andriole VT. Future role and uses of the quinolones. In: Neu HC, editor. Quinolones: the present and the future. Infect Dis Clin Pract 1994; 3: S211-S217
4. Gellert M, Mizuuchi K, O'Dea MH, et al. DNA gyrase; an enzyme that introduces superhelical turns in DNA. Proc Natl Acad Sci USA 1976; 73: 3872-6
5. Higgins NP, Peebles CL, Sugino A, et al. Purification of subunits of Escherichia coli, DNA gyrase and reconstitution of enzymic activity. Proc Natl Acad Sci USA 1978; 75: 1773
6. Pedrini A. Nalidixic acid. In: Hahn FE, editor. Antibiotics. Berlin: Springer-Verlag, 1979
7. Wang, JC. Interactions between twisted DNAs and enzymes: the effect of superhelical turns. J Mol Biol 1974; 87: 797-816
8. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97
9. Gellert M, Mizuuchi K, O'Dea MH, et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1977; 74: 3872
10. Smith JT, Lewin CS. Chemistry and mechanisms of action of the quinolone antibacterials. In: Andriole VT, editor. The quinolones. London: Academic Press, 1988: 23-81
11. Sugino A, Peebles CL, Krenzer KN, et al. Mechanism of action of nalidixic acid: purification of E. coli nalA gene pro duct and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci USA 1977; 74: 4767-71
12. Crumplin GC, Smith JT. Nalidixic acid and bacterial chromosome replication. Nature 1976; 260: 643-5
13. Andriole VT. Quinolones. In: Gorbach S, editor. Infectious diseases. Philadelphia: Saunders, 1998: 275-89
14. Neu HC. Quinolone antimicrobial agents. Annu Rev Med 1992; 43: 465-86
15. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706
16. Gootz TD, Brighty KE. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Med Res Rev 1996; 16: 433-86
17. Phillips I, King A, Shannon K. In vitro properties of the quinolones. In: Andriole VT, editor. The quinolones. London: Academic Press, 1998: 81-116
18. Hooper DC, Wolfson JS. Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis 1991; 10: 223-31
19. Nikaido H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 1993; 37: 1393-9
20. Aoyama H, Fujimaki K, Sato K, et al. Clinical isolate of Citrobacter freundii highly resistant to new quinolones. Antimicrob Agents Chemother 1988; 32: 922-4
21. Kitamura A, Hoshino K, Kimura Y, et al. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1467-71
22. Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemother 1995; 36: 293-301
23. Ito T, Matsumoto M, Nishino T. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci. Antimicrob Agents Chemother 1995; 39: 1522-5
24. Kitani H, Kuroda T, Moriguchi A, et al. Synthesis and structural optimization of 7-3-(3,3-disubstituted-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8- methoxy-4-oxo-3-quinolinecarboxylic acids as antibacterial agents. Bioorg Med Chem Lett 1997; 7: 515-20
25. Maejima T, Senda H, Iwatani W, et al. Potent antibacterial activity of S-32730, a new fluoroquinolone against Gram-positive bacteria including quinolone-resistant MRSA [abstract F-189]. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995: San Francisco. Washington DC: American Society for Microbiology, 1995
26. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-11
27. Applebaum PC. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995; 49 Suppl. 2: 76-80
28. Aldridge KE, Ashcraft D, Bowman KA. Comparative in vitro activities of trovafloxacin (CP-99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother 1997; 41: 484-7
29. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996; 23 Suppl. 1: 2-8
30. Bergan T. Pharmacokinetics of the fluoroquinolones. In: Andriole VT, editor. The quinolones. London: Academic Press, 1998: 143-82
31. Kimura Y, Atarashi S, Kawakami K, et al. I. (Fluorocyclopropyl) quinolones. 2. Synthesis and stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl) quinolone antibacterial agents. J Med Chem 1994; 37: 3344-52
32. Andriole VT. Clinical overview of the newer 4-quinolone antibacterial agents. In: Andriole VT, editor. The quinolones. London: Academic Press, 1988: 155-200
33. Andriole VT. Quinolones. In: Andriole VT, editor. Current infectious disease drugs. Philadelphia: Current Medicine, 1996: 148-63
34. Hopkins S, Williams D, Dunne M, et al. A randomized controlled trial of oral or intravenous trovafloxacin vs ceftriaxone in the treatment of epidemic meningococcal meningitis [abstract LB-21]. Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans. Washington DC: American Society for Microbiology, 1996
35. Rolston KVI. Use of the quinolones in immunocompromised patients. In: Andriole VT, editor. The quinolones. London: Academic Press, 1998: 303-26
36. Stahlmann R, Lode H. Safety overview: toxicity, adverse effects and drug interactions. In: Andriole VT, editor. The quinolones. London: Academic Press, 1998: 369-415
37. Church DA, Echols RM, Co-chairpersons. Ciprofloxacin use in pediatric and cystic fibrosis patients. Pediatr Infect Dis J 1997; 16: 89-162
38. Giamarellou H, Kilokythas E, Petrikkos G, et al. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 1989; 87 Suppl. 5A: 49-51
39. Kim JH, Kang JA, Kim YG, et al. In vitro and in vivo anti-bacterial efficacies of CFC-222, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 2209-13
40. Miyazaki S, Domon H, Tateda K, et al. In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections. Antimicrob Agents Chemother 1997; 41: 2582-5
41. Meyerhoff C, Dilger C, Yoon SJ, et al. Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. J Antimicrob Chemother 1998; 42: 349-61
42. Carbone M, Fera MT, Cecchetti V, et al. In vitro activities of new quinolones against Helicobacter pylori. Antimicrob Agents Chemother 1997; 41: 2790-2
43. Andriole VT. The quinolones: prospects. In: Andriole VT, editor. The quinolones. London: Academic Press, 1998: 417-29
44. Cunha BA, Hussain Qadri SM, Ueno Y, et al. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J Antimicrob Chemother 1997; 39 Suppl. B: 29-34
45. Felmingham D, Robbins MJ, Ingley K, et al. In vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997; 39 Suppl. B: 43-50
46. Klugman KP, Gootz TD. In vitro and in vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1997; 39 Suppl. B: 51-6
47. Sefton AM, Maskeell JP, Rafay AM, et al. The in vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. J Antimicrob Chemother 1997; 39 Suppl. B: 57-62
48. Taba H, Kusano N. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob Agents Chemother 1998; 42: 2193-6
49. Bebear CM, Renaudin H, Charron A, et al. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother 1998; 42: 2304-11
50. Gonzalez I, Georgiou M, Alcaide F, et al. Fluoroquinolone resistance mutations in the parC, parE and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother 1998; 41: 2792-8
51. Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2810-6
52. Piddock LJV, Johnson M, Ricci V, et al. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998; 42: 2956-60
53. Dong Y, Xu C, Zhao X, et al. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival and resistance. Antimicrob Agents Chemother 1998; 42: 2978-84
54. Tanaka M, Onodera Y, Uchida Y, et al. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus. Antimicrob Agents Chemother 1998; 42: 3044-6
55. Schaad UB. Use of the quinolones in pediatrics. In: Andriole VT, editor. The quinolones. London, Academic Press, 1998; 351-67
56. Huovinen P, Wolfson JS, Hooper DC. Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates. Eur J Microbiol Infect Dis 1992; 11: 255-7
57. Giamarellos-Bourboulis EJ, Sambatakou H, Grecka P, et al. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium. Eur J Clin Microbiol Infect Dis 1998; 17: 657-61